Biotech start-up Diabetica has announced a worldwide licensing agreement with a US pharmaceutical that could earn the company up to €34 million.
The deal provides Californian-based Amylin Pharmaceuticals with exclusive rights to Diabetica’s intellectual property for the development of glucose-dependent insulinotropic polypeptide (GIP) agonists.
Modified forms of GIP, a naturally occurring molecule produced by the body, can combat key symptoms of diabetes.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team